Sumatriptan Pliva may be available in the countries listed below.
Sumatriptan succinate (a derivative of Sumatriptan) is reported as an ingredient of Sumatriptan Pliva in the following countries:
International Drug Name Search
Cardoxone may be available in the countries listed below.
Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Cardoxone in the following countries:
International Drug Name Search
Forumen may be available in the countries listed below.
Docusate Sodium is reported as an ingredient of Forumen in the following countries:
International Drug Name Search
Generic Name: desonide topical (DES oh nide)
Brand Names: Delonide, Desonate, DesOwen, DesOwen 2 oz, DesOwen Lotion 4 oz Kit, LoKara, Tridesilon, Verdeso
Desonide is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.
Desonide topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.
Desonide topical may also be used for other purposes not listed in this medication guide.
Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.
Before using desonide topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.
Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.
Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.
Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.
To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.
Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.
An overdose of desonide is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.
Desonide topical should not be used to treat any skin condition your doctor has not prescribed it for.
blurred vision, or seeing halos around lights;
mood changes;
sleep problems (insomnia);
weight gain, puffiness in your face; or
muscle weakness, feeling tired.
Less serious side effects may include:
mild skin itching, redness, burning, or peeling;
dryness or scaly skin;
thinning or softening of your skin;
skin rash or irritation around your mouth;
swollen hair follicles;
changes in color of treated skin;
blisters, pimples, or crusting of treated skin; or
stretch marks.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
It is not likely that other drugs you take orally or inject will have an effect on topically applied desonide topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: DesOwen side effects (in more detail)
Finoxaline may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Flunixin meglumine (a derivative of Flunixin) is reported as an ingredient of Finoxaline in the following countries:
Oxytetracycline hydrochloride (a derivative of Oxytetracycline) is reported as an ingredient of Finoxaline in the following countries:
International Drug Name Search
Zolaram may be available in the countries listed below.
Alprazolam is reported as an ingredient of Zolaram in the following countries:
International Drug Name Search
Klomazole may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Klomazole in the following countries:
International Drug Name Search
Terbulin may be available in the countries listed below.
Terbutaline sulfate (a derivative of Terbutaline) is reported as an ingredient of Terbulin in the following countries:
International Drug Name Search
Nitrendipin Basics may be available in the countries listed below.
Nitrendipine is reported as an ingredient of Nitrendipin Basics in the following countries:
International Drug Name Search
Lactulose Sandoz may be available in the countries listed below.
Lactulose is reported as an ingredient of Lactulose Sandoz in the following countries:
International Drug Name Search
Cimetidin AL may be available in the countries listed below.
Cimetidine is reported as an ingredient of Cimetidin AL in the following countries:
International Drug Name Search
Erben may be available in the countries listed below.
Berberine sulfate (a derivative of Berberine) is reported as an ingredient of Erben in the following countries:
Berberine tannate (a derivative of Berberine) is reported as an ingredient of Erben in the following countries:
International Drug Name Search
Estreptomicina may be available in the countries listed below.
Streptomycin sulfate (a derivative of Streptomycin) is reported as an ingredient of Estreptomicina in the following countries:
International Drug Name Search
Rimactan may be available in the countries listed below.
Rifampicin is reported as an ingredient of Rimactan in the following countries:
Rifampicin sodium salt (a derivative of Rifampicin) is reported as an ingredient of Rimactan in the following countries:
International Drug Name Search
Glucosamina Bexal may be available in the countries listed below.
Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Glucosamina Bexal in the following countries:
International Drug Name Search
Fluor Oligosol may be available in the countries listed below.
Sodium Fluoride is reported as an ingredient of Fluor Oligosol in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
USP
D01AE04,D01AE54
0000112-38-9
C11-H20-O2
184
Antifungal agent
10-Undecenoic acid
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| USP | Pharmacopoeia of the United States |
Simvalimit may be available in the countries listed below.
Simvastatin is reported as an ingredient of Simvalimit in the following countries:
International Drug Name Search
Fursol may be available in the countries listed below.
Furosemide is reported as an ingredient of Fursol in the following countries:
International Drug Name Search
Philazole Shampooing may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Philazole Shampooing in the following countries:
International Drug Name Search
Doksy may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doksy in the following countries:
International Drug Name Search
Sigabroxol may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Sigabroxol in the following countries:
International Drug Name Search
Klaider may be available in the countries listed below.
Fluconazole is reported as an ingredient of Klaider in the following countries:
International Drug Name Search
Dolevar may be available in the countries listed below.
Paracetamol is reported as an ingredient of Dolevar in the following countries:
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Dolevar in the following countries:
International Drug Name Search
Digosin may be available in the countries listed below.
Digoxin is reported as an ingredient of Digosin in the following countries:
International Drug Name Search
Diasectral may be available in the countries listed below.
Acebutolol hydrochloride (a derivative of Acebutolol) is reported as an ingredient of Diasectral in the following countries:
International Drug Name Search
UK matches:
Erythromycin Lactobionate (BANM, JAN) is known as Erythromycin in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| JAN | Japanese Accepted Name |
| SPC | Summary of Product Characteristics (UK) |
Acetazolamid may be available in the countries listed below.
Acetazolamide is reported as an ingredient of Acetazolamid in the following countries:
International Drug Name Search
ratio-Temazepam may be available in the countries listed below.
Temazepam is reported as an ingredient of ratio-Temazepam in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
0000070-26-8
C5-H12-N2-O2
132
Hepatoprotective agent
L-Ornithine
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Domperidon Hexal may be available in the countries listed below.
Domperidone maleate (a derivative of Domperidone) is reported as an ingredient of Domperidon Hexal in the following countries:
International Drug Name Search
Stamifen may be available in the countries listed below.
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Stamifen in the following countries:
International Drug Name Search
Lovastatin-Teva may be available in the countries listed below.
Lovastatin is reported as an ingredient of Lovastatin-Teva in the following countries:
International Drug Name Search
Mesna Richmond may be available in the countries listed below.
Mesna is reported as an ingredient of Mesna Richmond in the following countries:
International Drug Name Search
Bermoxel may be available in the countries listed below.
Praziquantel is reported as an ingredient of Bermoxel in the following countries:
International Drug Name Search
Onyster may be available in the countries listed below.
Urea is reported as an ingredient of Onyster in the following countries:
International Drug Name Search
PhotoBarr may be available in the countries listed below.
Porfimer Sodium is reported as an ingredient of PhotoBarr in the following countries:
International Drug Name Search
brand of augmented betamethasone dipropionate1
Lotion 0.05% (potency expressed as betamethasone)
For Dermatologic Use Only — Not for Ophthalmic Use
PRODUCT INFORMATION
DIPROLENE® (augmented betamethasone dipropionate) Lotion contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone.
Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula:
It is a white to creamy-white, odorless powder insoluble in water; freely soluble in acetone and in chloroform; sparingly soluble in alcohol.
Each gram of Diprolene Lotion 0.05% contains 0.643 mg betamethasone dipropionate, USP (equivalent to 0.5 mg betamethasone), in an augmented lotion base of purified water; isopropyl alcohol (30%); hydroxypropyl cellulose; propylene glycol; sodium phosphate; phosphoric acid and sodium hydroxide used to adjust the pH.
The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects.
Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see DOSAGE AND ADMINISTRATION).
Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see DOSAGE AND ADMINISTRATION).
Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver, and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Studies performed with DIPROLENE® Lotion indicate that it is in the super-high range of potency as compared with other topical corticosteroids.
DIPROLENE® Lotion is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. The total dose should not exceed 50 mL per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
DIPROLENE® Lotion is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure (see DOSAGE AND ADMINISTRATION).
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Patients should not be treated with amounts of DIPROLENE® Lotion greater than 50 mL per week because of the potential for the drug to suppress HPA axis. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression.
Diprolene Lotion was applied once daily at 7 mL per day for 21 days to diseased scalp and body skin in patients with scalp psoriasis to study its effects on the HPA axis. In 2 out of 11 patients, the drug lowered plasma cortisol levels below normal limits. HPA axis suppression in these patients was transient and returned to normal within a week. In one of these patients, plasma cortisol levels returned to normal while treatment continued.
Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS, Pediatric Use section).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Diprolene Lotion should not be used in the treatment of rosacea or perioral dermatitis, and it should not be used on the face, groin, or in the axillae.
Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
The following tests may be helpful in evaluating patients for HPA axis suppression:
Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate. Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone. Studies in rabbits, mice, and rats using intramuscular doses up to 1, 33, and 2 mg/kg, respectively, resulted in dose-related increases in fetal resorptions in rabbits and mice.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2 times the human topical dose of Diprolene Lotion in mg/m2 of body surface area, assuming 100% absorption and the use in a 60 kg person of 7 g per day. The abnormalities observed included umbilical hernias, cephalocele, and cleft palate. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Diprolene Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Diprolene Lotion is administered to a nursing woman.
Use of Diprolene Lotion, 0.05%, in pediatric patients 12 years of age and younger is not recommended (see CLINICAL PHARMACOLOGY and ADVERSE REACTIONS).
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children.
Seven clinical studies of Diprolene Lotion evaluated 407 subjects of which 56 subjects were 65 years of age and over and 9 subjects were 75 years of age and over. No overall differences in safety or effectiveness were observed in these clinical studies between geriatric subjects and younger subjects. There was a numerical difference for application site reactions (most frequently reported events were burning and stinging) which occurred in 15% (10/65) of geriatric subjects and 11% (38/342) of subjects less than 65 years of age. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.
The local adverse reactions which were reported with DIPROLENE® Lotion during controlled clinical trials were as follows: erythema, folliculitis, pruritus, and vesiculation each occurring in less than 1% of patients.
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Topically applied DIPROLENE® Lotion can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
Apply a few drops of DIPROLENE® Lotion to the affected skin once or twice daily and massage lightly until the lotion disappears.
Diprolene Lotion is a super-high potency topical corticosteroid. Treatment with Diprolene Lotion should be limited to two weeks, and amounts greater than 50 mL per week should not be used.
As with other highly active corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Diprolene Lotion should not be used with occlusive dressings. Diprolene Lotion should not be applied to the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
DIPROLENE® Lotion 0.05% is supplied in 30-mL (29 g) (NDC 0085-0962-01) and 60-mL (58 g) (NDC 0085-0962-02) plastic squeeze bottles; boxes of one.
Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].
Rev. 5/07
Copyright © 1988, 2004, Schering Corporation. All rights reserved.
B-23409852
23816431T
| DIPROLENE betamethasone dipropionate lotion | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
Cefalexina Sant Gall may be available in the countries listed below.
Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Cefalexina Sant Gall in the following countries:
International Drug Name Search
SPMC Amoxycillin may be available in the countries listed below.
Amoxicillin is reported as an ingredient of SPMC Amoxycillin in the following countries:
International Drug Name Search
Generic Name: oxazepam (ox A ze pam)
Brand Names: Serax
Oxazepam is in a group of drugs called benzodiazepines (ben-zoe-dye-AZE-eh-peens). Oxazepam affects chemicals in the brain that may become unbalanced and cause anxiety.
Oxazepam is used to treat anxiety disorders or alcohol withdrawal symptoms.
Oxazepam may also be used for other purposes not listed in this medication guide.
Before taking oxazepam, tell your doctor if you have any breathing problems, glaucoma, porphyria, kidney or liver disease, or a history of depression, suicidal thoughts, or addiction to drugs or alcohol.
Treatments for depression are getting better everyday and there are things you can start doing right away.
Avoid using other medicines that make you sleepy. They can add to sleepiness caused by oxazepam.
Before taking oxazepam, tell your doctor if you are allergic to any drugs, or if you have:
glaucoma;
asthma, emphysema, bronchitis, chronic obstructive pulmonary disorder (COPD), or other breathing problems;
kidney or liver disease;
a history of depression or suicidal thoughts or behavior; or
a history of drug or alcohol addiction.
If you have any of these conditions, you may need a dose adjustment or special tests to safely take this medication.
Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.
Your doctor may occasionally change your dose to make sure you get the best results from this medication.
Your symptoms may return when you stop using oxazepam after using it over a long period of time. You may also have seizures or withdrawal symptoms when you stop using oxazepam. Withdrawal symptoms may include tremor, sweating, trouble sleeping, muscle cramps, stomach pain, vomiting, diarrhea, confusion, unusual thoughts or behavior, and seizure (convulsions).
To be sure this medication is not causing harmful effects, your doctor will need to check your progress on a regular basis. Do not miss any scheduled visits to your doctor.
Keep track of how many pills have been used from each new bottle of this medicine. Benzodiazepines are drugs of abuse and you should be aware if any person in the household is using this medicine improperly or without a prescription.
See also: Oxazepam dosage (in more detail)
Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include extreme drowsiness, confusion, weakness or tired feeling, muscle weakness, loss of balance or coordination, feeling light-headed, fainting, or coma.
Tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures or depression). They can add to sleepiness caused by oxazepam.
confusion;
unusual risk-taking behavior, decreased inhibitions, no fear of danger;
hyperactivity, agitation, hostility;
hallucinations;
feeling lightheaded, fainting;
jaundice (yellowing of the skin or eyes); or
problems with urination.
Less serious side effects may include:
drowsiness, dizziness;
amnesia or forgetfulness, trouble concentrating;
slurred speech;
swelling;
headache;
skin rash;
nausea, vomiting, constipation;
irregular menstrual periods; or
loss of interest in sex.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Anxiety:
For mild to moderate anxiety: 10 to 15 mg orally 3 to 4 times a day.
For severe anxiety: 15 to 30 mg orally 3 to 4 times a day.
Usual Adult Dose for Alcohol Withdrawal:
15 to 30 mg orally 3 to 4 times a day for alcoholics with acute inebriation, tremulousness, or anxiety on withdrawal.
Usual Geriatric Dose for Anxiety:
Initial dose: 10 mg orally 3 times a day.
If necessary, increase cautiously to 15 mg orally 3 to 4 times a day.
Usual Pediatric Dose for Anxiety:
The safety and efficacy of oxazepam in children
>= 6 years to 12 years: 1 mg/kg/day.
>= 13 years: For mild to moderate anxiety: 10 to 15 mg orally 3 to 4 times a day.
For severe anxiety: 15 to 30 mg orally 3 to 4 times a day.
Before taking oxazepam, tell your doctor if you are using any of the following drugs:
a barbiturate such as amobarbital (Amytal), butabarbital (Butisol), mephobarbital (Mebaral), secobarbital (Seconal), or phenobarbital (Luminal, Solfoton);
an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate);
medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), pimozide (Orap), or thioridazine (Mellaril);
narcotic medications such as butorphanol (Stadol), codeine, hydrocodone (Lortab, Vicodin), levorphanol (Levo-Dromoran), meperidine (Demerol), methadone (Dolophine, Methadose), morphine (Kadian, MS Contin, Oramorph), naloxone (Narcan), oxycodone (OxyContin), propoxyphene (Darvon, Darvocet); or
antidepressants such as amitriptyline (Elavil, Etrafon), amoxapine (Asendin), citalopram (Celexa), clomipramine (Anafranil), desipramine (Norpramin), doxepin (Sinequan), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), imipramine (Janimine, Tofranil), nortriptyline (Pamelor), paroxetine (Paxil), protriptyline (Vivactil), sertraline (Zoloft), or trimipramine (Surmontil).
This list is not complete and there may be other drugs that can interact with oxazepam. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: oxazepam side effects (in more detail)
Rispéridone may be available in the countries listed below.
Rispéridone (DCF) is known as Risperidone in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Terbosulfa may be available in the countries listed below.
Sulfamethoxazole is reported as an ingredient of Terbosulfa in the following countries:
Trimethoprim is reported as an ingredient of Terbosulfa in the following countries:
International Drug Name Search
Dracanyl may be available in the countries listed below.
Terbutaline sulfate (a derivative of Terbutaline) is reported as an ingredient of Dracanyl in the following countries:
International Drug Name Search
Gen-Eti-Cal Carepac may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Gen-Eti-Cal Carepac in the following countries:
Etidronic Acid disodium salt (a derivative of Etidronic Acid) is reported as an ingredient of Gen-Eti-Cal Carepac in the following countries:
International Drug Name Search
Digestase may be available in the countries listed below.
Pancreatin is reported as an ingredient of Digestase in the following countries:
International Drug Name Search
Optbac may be available in the countries listed below.
Chloramphenicol is reported as an ingredient of Optbac in the following countries:
International Drug Name Search
Dexibu may be available in the countries listed below.
Dexibuprofen is reported as an ingredient of Dexibu in the following countries:
International Drug Name Search
Avarin may be available in the countries listed below.
Alverine citrate (a derivative of Alverine) is reported as an ingredient of Avarin in the following countries:
Simeticone is reported as an ingredient of Avarin in the following countries:
International Drug Name Search
Diltiem may be available in the countries listed below.
Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Diltiem in the following countries:
International Drug Name Search
Oophormin Luteum may be available in the countries listed below.
Hydroxyprogesterone caproate (a derivative of Hydroxyprogesterone) is reported as an ingredient of Oophormin Luteum in the following countries:
International Drug Name Search
Staphlex may be available in the countries listed below.
Flucloxacillin is reported as an ingredient of Staphlex in the following countries:
Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Staphlex in the following countries:
International Drug Name Search
Concatag may be available in the countries listed below.
Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Concatag in the following countries:
International Drug Name Search
Genestran may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cloprostenol is reported as an ingredient of Genestran in the following countries:
Cloprostenol sodium salt (a derivative of Cloprostenol) is reported as an ingredient of Genestran in the following countries:
International Drug Name Search
Rino-Lastin may be available in the countries listed below.
Azelastine hydrochloride (a derivative of Azelastine) is reported as an ingredient of Rino-Lastin in the following countries:
International Drug Name Search
Vorange may be available in the countries listed below.
Ascorbic Acid is reported as an ingredient of Vorange in the following countries:
International Drug Name Search
Risperdal Flas may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperdal Flas in the following countries:
International Drug Name Search
Risperidona Medispes may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperidona Medispes in the following countries:
International Drug Name Search
In the US, Mineral Oil (mineral oil systemic) is a member of the drug class laxatives.
US matches:
Mineral Oil (USAN) is also known as Paraffin liquid (Ph. Eur.)
International Drug Name Search
Glossary
| Ph. Eur. | European Pharmacopoeia |
| USAN | United States Adopted Name |
Chinidinã Sulfat may be available in the countries listed below.
Quinidine sulfate (a derivative of Quinidine) is reported as an ingredient of Chinidinã Sulfat in the following countries:
International Drug Name Search
Fosalen may be available in the countries listed below.
Alendronic Acid is reported as an ingredient of Fosalen in the following countries:
Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Fosalen in the following countries:
International Drug Name Search
Gidacid may be available in the countries listed below.
Ciclopirox olamine (a derivative of Ciclopirox) is reported as an ingredient of Gidacid in the following countries:
International Drug Name Search
Gynafem may be available in the countries listed below.
Butoconazole nitrate (a derivative of Butoconazole) is reported as an ingredient of Gynafem in the following countries:
International Drug Name Search
Paroxetin Heumann may be available in the countries listed below.
Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetin Heumann in the following countries:
International Drug Name Search
Moxonidin-Isis may be available in the countries listed below.
Moxonidine is reported as an ingredient of Moxonidin-Isis in the following countries:
International Drug Name Search
Nordette-28 is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Nordette-28:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nordette-28. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Nordette-28.
Domperidona Generis may be available in the countries listed below.
Domperidone is reported as an ingredient of Domperidona Generis in the following countries:
International Drug Name Search
Oramox may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Oramox in the following countries:
International Drug Name Search
Citicoline H may be available in the countries listed below.
Citicoline is reported as an ingredient of Citicoline H in the following countries:
International Drug Name Search
Pravastatina Lipra may be available in the countries listed below.
Pravastatin is reported as an ingredient of Pravastatina Lipra in the following countries:
International Drug Name Search
Tioconazol Korhispana may be available in the countries listed below.
Tioconazole is reported as an ingredient of Tioconazol Korhispana in the following countries:
International Drug Name Search
